Whither Autoimmunity: The Lessons of Anti-CCP and B cell Depletion Yehuda ShoenfeldM. Eric Gershwin OriginalPaper 09 September 2007 Pages: 1 - 3
Antibodies to Citrullinated Vimentin are a Specific and Sensitive Marker for the Diagnosis of Rheumatoid Arthritis Hannah PoulsomPeter J. Charles OriginalPaper 25 September 2007 Pages: 4 - 10
Does the Presence of Anti-CCP Autoantibodies and Their Serum Levels Influence the Severity and Activity in Rheumatoid Arthritis Patients? Nikolaos G. PapadopoulosGeorgios Z. TsiaousisVassiliki K. Galanopoulou OriginalPaper 13 September 2007 Pages: 11 - 15
Diagnostic Accuracy of Immunoassays for the Detection of Antibodies to Citrullinated Proteins Nicola BizzaroMarilina Tampoia OriginalPaper 19 September 2007 Pages: 16 - 20
Comparison of Three Anti-CCP Antibody Tests and Rheumatoid Factor in RA and Control Patients Ma Lurdes CorreiaSaudade CarvalhoMa Henriqueta Pereira OriginalPaper 18 September 2007 Pages: 21 - 25
Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis: As Good as it Gets? Zoltán SzekaneczLilla SoósGabriella Lakos OriginalPaper 21 September 2007 Pages: 26 - 31
Share Epitope, Citrullinated Cyclic Peptide Antibodies and Smoking in Brazilian Rheumatoid Arthritis Patients Rene Donizeti OliveiraCristina Maria JuntaPaulo Louzada-Junior OriginalPaper 15 August 2007 Pages: 32 - 35
Anti-CCP2 Antibodies: An Overview and Perspective of the Diagnostic Abilities of this Serological Marker for Early Rheumatoid Arthritis Walther J. van VenrooijAlbert J. W. Zendman OriginalPaper Open access 18 September 2007 Pages: 36 - 39
Prevalence of Autoantibodies to Cyclic Citrullinated Peptide in Patients with Rheumatic Diseases other than Rheumatoid Arthritis: A French Multicenter Study Nicole FabienNils-Olivier OlssonJean Sibilia OriginalPaper 05 February 2008 Pages: 40 - 44
The Role of Anti-Cyclic Cytrullinate Antibodies Testing in Rheumatoid Arthritis Cristiano AlessandriRoberta PrioriGuido Valesini OriginalPaper 14 September 2007 Pages: 45 - 49
B-Cell Depletion and Repopulation in Autoimmune Diseases Jacques-Olivier PersCapucine DaridonPierre Youinou OriginalPaper 06 September 2007 Pages: 50 - 55
Rituximab in Treatment-Resistant Autoimmune Blistering Skin Disorders Enno SchmidtEva-Bettina BröckerMatthias Goebeler OriginalPaper 04 September 2007 Pages: 56 - 64
Analysis of Wegener’s Granulomatosis Responses to Rituximab: Current Evidence and Therapeutic Prospects Achille AoubaChristian PagnouxLoïc Guillevin OriginalPaper 12 September 2007 Pages: 65 - 73
Rituximab: Beyond Simple B Cell Depletion A. KesselI. RosnerE. Toubi OriginalPaper 01 February 2008 Pages: 74 - 79
Combined Therapy with Rituximab Plus Cyclophosphamide/Vincristine/Prednisone for Sjogren’s Syndrome-Associated B-Cell Non-Hodgkin’s Lymphoma J. CarboneR. Perez-FernandezE. Fernandez-Cruz OriginalPaper 22 August 2007 Pages: 80 - 84
Hepatitis B Virus (HBV) and Autoimmune Disease Ram MayaM. Eric GershwinYehuda Shoenfeld OriginalPaper 18 September 2007 Pages: 85 - 102
Rituximab Off Label Use for Difficult-To-Treat Auto-Immune Diseases: Reappraisal of Benefits and Risks Laurent Sailler OriginalPaper 07 September 2007 Pages: 103 - 110
Rituximab as a Therapeutic Tool in Severe Mixed Cryoglobulinemia Dario RoccatelloSimone BaldovinoLuigi M. Sena OriginalPaper 21 August 2007 Pages: 111 - 117
Rituximab Induces Distinct Intraorbital and Intrathyroidal Effects in One Patient Satisfactorily Treated for Graves’ Ophthalmopathy P. BonaraG. VannucchiM. Salvi OriginalPaper 18 September 2007 Pages: 118 - 123
Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases? Claudio GalarzaDiana ValenciaJuan-Manuel Anaya OriginalPaper 22 September 2007 Pages: 124 - 128
